Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 1, 2015, Pages 47-53

  Boylan, B ^a   Rice, A S ^a   Miller, C H ^a   Dunn, A L ^b,f   Abshire, T C ^b   Kempton, C L ^b   Tarantino, M D ^c   Brettler, D B ^d   Barrett, J C ^e   Bockenstedt, P L ^g   Di Paola, J A ^h   Radhi, M ^h   Lentz, S R ^h   Massey, G ^e   Neff, A T ⁱ   Shapiro, A D ^j   Wicklund, B M ^k   Manco Johnson, M J ^l   Knoll, C ^m   Escobar, M A ⁿ   Elaine Eyster, M ^o   Gill, J C ^p   Leissinger, C ^q   Yaish, H ^r   more..

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b EMORY UNIVERSITY   (United States)

^c Bleeding and Clotting Disorders Institute   (United States)

^d New England Hemophilia Center   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^k Kansas City Regional Hemophilia Treatment Center   (United States)

^l Mountain States Regional Hemophilia and Thrombosis Center   (United States)

^m PHOENIX CHILDREN'S HOSPITAL   (United States)

ⁿ Gulf States Hemophilia and Thrombophilia Center   (United States)

^o Hemophilia Center of Central Pennsylvania   (United States)

^p Comprehensive Center for Bleeding Disorders ^*  (United States)

^q The Louisiana Center for Bleeding and Clotting Disorders   (United States)

^r PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

more..

Author keywords

Factor VIII; Factor VIII deficiency; Hemophilia A; Immunoassay; Inherited blood coagulation disorders

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; F8 PROTEIN, HUMAN; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FLUORESCENCE; HEMOPHILIA A; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; BLOOD; FLUORESCENCE POLARIZATION IMMUNOASSAY; IMMUNOLOGY; MALE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; SPECTROFLUOROMETRY; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; AUTOANTIBODIES; BIOMARKERS; FACTOR VIII; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN G; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SPECTROMETRY, FLUORESCENCE; TIME FACTORS; YOUNG ADULT;

EID: 84921064464     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12768     Document Type: Article

References (30)

1. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576-81.
2. Kruse-Jarres R. Inhibitors: our greatest challenge. Can we minimize the incidence? Haemophilia 2013; 19(Suppl. 1): 2-7.
3. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
4. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009; 7: 1446-56.
5. DiMichele DM. Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 2012; 159: 123-34.
6. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
7. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia 2012; 18: 268-75.
8. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
9. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
10. Blanco AN, Alcira PA, Grosso SH, Gennari LC, Perez BR, Lazzari MA. A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant. Haematologica 2002; 87: 271-8.
11. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
12. Whelan SF, Hofbauer CJ, Horling FM, Allacher P, Wolfsegger MJ, Oldenburg J, Male C, Windyga J, Tiede A, Schwarz HP, Scheiflinger F, Reipert BM. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121: 1039-48.
13. Lewis KB, Hughes RJ, Epstein MS, Josephson NC, Kempton CL, Kessler CM, Key NS, Howard TE, Kruse-Jarres R, Lusher JM, Walsh CE, Watts RG, Ettinger RA, Pratt KP. Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. PLoS ONE 2013; 8: e61120.
14. Nguyen PC, Lewis KB, Ettinger RA, Schuman JT, Lin JC, Healey JF, Meeks SL, Lollar P, Pratt KP. High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance. Blood 2014; 123: 2732-9.
15. Lavigne-Lissalde G, Tarrade C, Lapalud P, Chtourou S, Schved JF, Granier C, Villard-Saussine S. Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 2008; 99: 1090-6.
16. Krudysz-Amblo J, Parhami-Seren B, Butenas S, Brummel-Ziedins KE, Gomperts ED, Rivard GE, Mann KG. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113: 2587-94.
17. Zakarija A, Harris S, Rademaker AW, Brewer J, Krudysz-Amblo J, Butenas S, Mann KG, Green D. Alloantibodies to factor VIII in haemophilia. Haemophilia 2011; 17: 636-40.
18. Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost 2013; 11: 1300-9.
19. Lebreton A, Lapalud P, Chambost H, Biron-Andreani C, Morange PE, Combescure C, Marques-Verdier A, Berger C, Schved JF, Granier C, Lavigne-Lissalde G. Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. Thromb Haemost 2011; 105: 954-61.
20. Towfighi F, Gharagozlou S, Sharifian RA, Kazemnejad A, Esmailzadeh K, Managhchi MR, Shokri F. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol 2005; 114: 84-90.
21. van Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, Mauser-Bunschoten EP, Aalberse RC, Vidarsson G, Voorberg J. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008; 142: 644-52.
22. Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia 2014; 20: 230-7.
23. Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 2012; 10: 1055-61.
24. Klintman J, Hillarp A, Berntorp E, Astermark J. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy. Br J Haematol 2013; 163: 385-92.
25. Ling M, Duncan EM, Rodgers SE, Street AM, Lloyd JV. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 2003; 1: 2548-53.
26. Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE, Peake IR. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-7.
27. De Barros MF, Herrero JC, Sell AM, De Melo FC, Braga MA, Pelissari CB, Machado J, De Souza SS, De Souza HL, Visentainer JE. Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil. Haemophilia 2012; 18: e236-40.
28. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
29. Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, Astermark J, Oldenburg J. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7: 2006-15.
30. Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.